Meeting Banner
Abstract #2919

Amide proton transfer (APT) MRI is a predictor of survival and progression in high-grade glioma patients

Daniel Paech1, Constantin Dreher1, Sebastian Regnery1, Jan-Eric Meissner2, Steffen Goerke2, Johannes Windschuh2, Katerina Deike-Hofmann1, Sebastian Bickelhaupt1, Alexander Radbruch3, Moritz Zaiss4, Andreas Unterberg5, Wolfgang Wick6, Martin Bendszus7, Peter Bachert2, Mark Edward Ladd2, and Heinz-Peter Schlemmer1

1Radiology, German Cancer Research Center, Heidelberg, Germany, 2Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, 3Radiology, University Hospital Essen, Essen, Germany, 4Max-Planck-Institut Tuebingen, Tuebingen, Germany, 5Neurosurgery, University of Heidelberg, Heidelberg, Germany, 6Neurology, University of Heidelberg, Heidelberg, Germany, 7Neuroradiology, University of Heidelberg, Heidelberg, Germany

In this work we show that relaxation-compensated amide proton transfer (APT) imaging at 7.0 T is associated with overall survival and progression-free survival in newly-diagnosed, previously untreated glioma patients. The current study showed that glioma patients with increased APT values were more likely to progress sooner and live shorter, respectively. This effect may be caused by strong alterations of amino acid concentrations and global upregulation of protein expression in more aggressive brain tumors. Therefore, APT CEST imaging may help to enhance the prognostic value of non-invasive MRI tools at the time of initial diagnosis and during follow-up.

This abstract and the presentation materials are available to members only; a login is required.

Join Here